Published in Continuum (Minneap Minn) on April 01, 2016
Clinical and Preclinical Cognitive Function Improvement after Oral Treatment of a Botanical Composition Composed of Extracts from Scutellaria baicalensis and Acacia catechu. Behav Neurol (2016) 0.75
An Overview of Systematic Reviews of Ginkgo biloba Extracts for Mild Cognitive Impairment and Dementia. Front Aging Neurosci (2016) 0.75
Altered peripheral profile of blood cells in Alzheimer disease: A hospital-based case-control study. Medicine (Baltimore) (2017) 0.75
Heparan sulfate proteoglycans and heparanases in Alzheimer's disease: current outlook and potential therapeutic targets. Neural Regen Res (2017) 0.75
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol (2003) 14.87
Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology (2007) 12.42
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83
Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.51
Dynamics of gray matter loss in Alzheimer's disease. J Neurosci (2003) 7.03
CSF markers for incipient Alzheimer's disease. Lancet Neurol (2003) 6.12
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology (2004) 5.86
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med (2008) 5.34
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol (2003) 3.75
Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 3.74
Prevalence of dementia in older latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. J Am Geriatr Soc (2003) 3.60
Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ (2007) 3.30
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol (1995) 3.23
Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med (1998) 3.23
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol (2001) 3.19
Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol (2002) 3.17
Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA (2002) 3.16
Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol (2006) 3.11
Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol (1999) 3.03
Rates of dementia in three ethnoracial groups. Int J Geriatr Psychiatry (1999) 2.92
Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology (2005) 2.79
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol (1998) 2.77
Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiol Aging (1997) 2.68
Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev (2012) 2.25
Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc (1998) 1.88
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement (2013) 1.87
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology (2002) 1.58
Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. Arch Neurol (2007) 1.55
Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol (2011) 1.42
Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), and Alzheimer Disease. Alzheimer Dis Assoc Disord (2012) 1.40
3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Hum Brain Mapp (2010) 1.40
Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J (2012) 1.39
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid. Alzheimers Dement (2011) 1.30
Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med (2004) 1.22
Prevalence, laterality, and comorbidity of hippocampal sclerosis in an autopsy sample. Brain Behav (2012) 1.20
Genetics of Alzheimer's disease. Adv Genet (2014) 1.13
CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord (2006) 1.13
Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members. Neurology (2010) 1.00
Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology (2005) 0.98
Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD. Curr Alzheimer Res (2010) 0.98
Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS One (2015) 0.97
Reliability of two-dimensional and three-dimensional pseudo-continuous arterial spin labeling perfusion MRI in elderly populations: comparison with 15O-water positron emission tomography. J Magn Reson Imaging (2013) 0.94
Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry (2012) 0.92
Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia. Neuroimage Clin (2014) 0.91
Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol Genet Metab (2003) 0.86
Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging. Alzheimers Dement (2013) 0.85
Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of alzheimer dementia and detection of preclinical cortical amyloid. J Neuropathol Exp Neurol (2014) 0.84
Evaluation of dementia: a systematic study of the usefulness of the American Academy of Neurology's practice parameters. Neurology (1997) 0.84
Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials? Clin Ther (2015) 0.83
Relationship between hippocampal atrophy and neuropathology markers: a 7T MRI validation study of the EADC-ADNI Harmonized Hippocampal Segmentation Protocol. Alzheimers Dement (2015) 0.80
Comparison of two methods for the analysis of CSF Aβ and tau in the diagnosis of Alzheimer's disease. Am J Neurodegener Dis (2014) 0.78
Treatment of Mild Cognitive Impairment. Curr Treat Options Neurol (2015) 0.76
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.30
Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp (2009) 2.28
Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.25
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain (2007) 1.99
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
Comparison of AdaBoost and support vector machines for detecting Alzheimer's disease through automated hippocampal segmentation. IEEE Trans Med Imaging (2009) 1.80
Automatic subcortical segmentation using a contextual model. Med Image Comput Comput Assist Interv (2008) 1.25
Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiol Aging (2010) 1.22
Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. Neurobiol Aging (2012) 1.02
Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation. Neurosci Lett (2010) 1.00
Regional brain volume differences in symptomatic and presymptomatic carriers of familial Alzheimer's disease mutations. J Neurol Neurosurg Psychiatry (2012) 0.97
Verbal memory is associated with structural hippocampal changes in newly diagnosed Parkinson's disease. J Neurol Neurosurg Psychiatry (2012) 0.93
Multilocus genetic profiling to empower drug trials and predict brain atrophy. Neuroimage Clin (2013) 0.89
Establishing magnetic resonance images orientation for the EADC-ADNI manual hippocampal segmentation protocol. J Neuroimaging (2013) 0.86
Clinical, FDG and amyloid PET imaging in posterior cortical atrophy. J Neurol (2015) 0.86
Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there? Expert Rev Neurother (2006) 0.84
Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol (2015) 0.84
Agitation and psychosis associated with dementia with lewy bodies exacerbated by modafinil use. Am J Alzheimers Dis Other Demen (2012) 0.82
Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease. Mov Disord (2013) 0.82
Alzheimer disease: 'generation next' in Alzheimer disease genetic studies. Nat Rev Neurol (2013) 0.82
Mapping cortical atrophy in Parkinson's disease patients with dementia. J Parkinsons Dis (2013) 0.79
Similar verbal fluency patterns in amnestic mild cognitive impairment and Alzheimer's disease. Arch Clin Neuropsychol (2013) 0.79
Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort. Dement Geriatr Cogn Disord (2014) 0.79
Comparing hippocampal atrophy in Alzheimer's dementia and dementia with lewy bodies. Dement Geriatr Cogn Disord (2012) 0.77